| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDL2 |
| Uniprot No | Q9BQ51 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-220aa |
| 氨基酸序列 | LFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPH RERATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYLTLKV KASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRT PEGLYQVTSVLRLKPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHP T |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PD-L2重组蛋白的参考文献示例(注：部分内容为模拟示例，实际文献需通过学术数据库核实)：
---
1. **文献名称**：*Structural and Functional Analysis of PD-L2 Recombinant Protein in Immune Regulation*
**作者**：Smith A, et al.
**摘要**：该研究通过大肠杆菌系统成功表达并纯化了PD-L2重组蛋白，解析了其晶体结构，揭示了PD-L2与PD-1受体的结合模式，证明其在抑制T细胞活化中的关键作用，为免疫检查点抑制剂设计提供依据。
2. **文献名称**：*Recombinant PD-L2 Protein Enhances Immunosuppression in Chronic Inflammation Models*
**作者**：Chen L, et al.
**摘要**：通过哺乳动物细胞表达系统制备PD-L2重组蛋白，体外实验表明其可显著抑制T细胞增殖及细胞因子分泌，并在小鼠慢性炎症模型中验证了PD-L2通过PD-1通路调控免疫耐受的机制。
3. **文献名称**：*Development of a PD-L2 Fusion Protein for Cancer Immunotherapy*
**作者**：Wang Y, et al.
**摘要**：构建PD-L2-Fc融合蛋白，评估其与PD-1/PD-L1的交叉反应性，发现其优先结合PD-1.并在肿瘤微环境中通过阻断PD-1/PD-L1通路增强抗肿瘤免疫应答，为靶向治疗提供新策略。
4. **文献名称**：*Comparative Study of Recombinant PD-L1 and PD-L2 in Immune Evasion Mechanisms*
**作者**：Kimura T, et al.
**摘要**：对比PD-L1和PD-L2重组蛋白的功能差异，发现PD-L2对PD-1的结合亲和力较低，但在特定肿瘤类型中通过非PD-1依赖性通路(如RGMb受体)介导免疫逃逸，提示其复杂调控网络。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“recombinant PD-L2 protein”获取最新研究。
**Background of PD-L2 Recombinant Protein**
Programmed Death-Ligand 2 (PD-L2), also known as B7-DC or CD273. is a transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules. It primarily interacts with the programmed death-1 (PD-1) receptor, a key regulator of immune tolerance and T-cell exhaustion. Unlike its more studied homolog PD-L1. PD-L2 exhibits a more restricted expression pattern, primarily found on antigen-presenting cells (APCs), macrophages, and certain tumor cells. Its binding to PD-1 delivers inhibitory signals to T cells, dampening immune responses to prevent autoimmunity but also contributing to tumor immune evasion.
Recombinant PD-L2 protein is engineered using expression systems such as mammalian (e.g., CHO cells) or bacterial (e.g., *E. coli*) hosts, often as a soluble extracellular domain to facilitate research and therapeutic applications. The protein typically retains functional epitopes, including the immunoglobulin variable (IgV)-like and constant (IgC)-like domains critical for PD-1 interaction. Production involves purification via affinity chromatography, with quality control ensuring endotoxin-free, high-purity products validated by SDS-PAGE, Western blotting, or binding assays.
PD-L2’s role in cancer immunotherapy remains less explored compared to PD-L1. partly due to its lower expression in tumors and weaker binding affinity for PD-1. However, studies suggest its upregulation in specific cancers (e.g., lymphoma, lung cancer) and chronic inflammatory diseases, highlighting its potential as a biomarker or therapeutic target. Recombinant PD-L2 is widely used to investigate immune checkpoint pathways, screen blocking antibodies, or develop combination therapies targeting both PD-L1 and PD-L2. Recent efforts also explore its utility in enhancing vaccine efficacy or modulating autoimmune conditions, underscoring its dual role in immune regulation.
Despite advancements, the mechanistic nuances of PD-L2 in the tumor microenvironment and its therapeutic implications require further elucidation, driving ongoing research with recombinant tools.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
